Zacks' 7 Best Stocks for June, 2013
FREE Report for Zacks.com
Visitors Only

They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.

Today, you can see them free.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 06/18/2013

Company Name Symbol %Change
STAAR SURGIC STAA
10.98%
DTS INC DTSI
6.89%
ANIKA THERAP ANIK
6.04%
LUMOS NETWOR LMOS
5.70%
INSTEEL IND IIIN
5.28%

Symmetry Teams with UK Distributor

by Zacks Equity Research

February 28, 2013 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Symmetry Surgical, a subsidiary of orthopedic implants and instruments maker Symmetry Medical, Inc. (SMA - Analyst Report), recently signed a distribution agreement with renowned UK-based healthcare company, Hospital Innovations. As per the terms of the deal, Hospital Innovations will distribute Symmetry Surgical’s surgical instruments in UK.

Hospital Innovations distributes cutting-edge medical devices to about 400 hospitals across UK. The partnership will enable Symmetry Surgical to grow its customer base in the European market.

The distribution agreement is in line with Symmetry Surgical’s focus on worldwide expansion of its business inclusive of all brands under the erstwhile Codman Surgical Instruments. The company further plans to expand into other key European countries to gain healthy revenue opportunities.

Since Symmetry Medical’s core Original Equipment Manufacturer (“OEM”) Solutions business is facing declining capital spending, procedural and pricing pressure from the weak global orthopedic market, the company is focused on expanding its smaller Symmetry Surgical business.

Earlier, in Nov 2012, Symmetry Surgical collaborated with leading medical device distributor, MTG Medical Technologies (“MTG”) to sell its offerings in Europe. MTG, a subsidiary of Neuro-Competence, distributes cutting-edge yet affordable medical devices to hospitals located across Germany, Austria, Switzerland, Czech Republic, Hungary and Slovakia.

In the fourth quarter of 2012, revenues from the smaller Symmetry Surgical unit jumped 154% to $28.5 million, buoyed by the acquisition of Codman & Shurtleff, Inc., which contributed roughly $13.1 million to the division’s sales. Revenues also include a one-time purchase of an OEM Solutions client worth $2.9 million. Excluding the acquisition and the one-time purchase, sales increased 10.4% year over year in the quarter.

However, the company currently has a Zacks Rank #4 (Sell), as both revenues and earnings missed the Zacks Consensus Estimates in the fourth quarter of 2012. While we remain on the sidelines regarding Symmetry, companies such as Nuvasive Inc. (NUVA - Snapshot Report), Essilor International SA (ESLOY) and Cyberonics Inc. (CYBX - Analyst Report), each carrying a Zacks Rank #1 (Strong Buy), warrant a look.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.